US20030159944A1 - Apparatus for amperometric diagnostic anagnostic analysis - Google Patents

Apparatus for amperometric diagnostic anagnostic analysis Download PDF

Info

Publication number
US20030159944A1
US20030159944A1 US10/123,414 US12341402A US2003159944A1 US 20030159944 A1 US20030159944 A1 US 20030159944A1 US 12341402 A US12341402 A US 12341402A US 2003159944 A1 US2003159944 A1 US 2003159944A1
Authority
US
United States
Prior art keywords
electrode
cell
electrodes
sample
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/123,414
Inventor
Paul Pottgen
Neil Szuminsky
Jonathan Talbott
Joseph Jordan
Colina Jordan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tall Oak Ventures
Original Assignee
Tall Oak Ventures
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23527629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030159944(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tall Oak Ventures filed Critical Tall Oak Ventures
Priority to US10/123,414 priority Critical patent/US20030159944A1/en
Publication of US20030159944A1 publication Critical patent/US20030159944A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3273Devices therefor, e.g. test element readers, circuitry
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/817Enzyme or microbe electrode

Definitions

  • the present invention relates to a disposable electro-analytical cell and a method and apparatus for quantitatively determining the presence of biologically important compounds such as glucose; hormones, therapeutic drugs and the like from body fluids.
  • Diabetes and specifically diabetes mellitus, is a metabolic disease characterized by deficient insulin production by the pancreas which results in abnormal levels of blood glucose. Although this disease afflicts only approximately 4% of the population in the United States, it is the third leading cause of death following heart disease and cancer. With proper maintenance of the patient's blood sugar through daily injection of insulin, and strict control of dietary intake, the prognosis for diabetics is excellent. The blood glucose levels must, however, be closely followed in the patient either by clinical laboratory analysis or by daily analyses which the patient can conduct using relatively simple, non-technical, methods.
  • glucose oxidase catalyzes the conversion of B-D Glucose to D-Gluconic Acid.
  • the hydrogen peroxide produced is measured by reflectance spectroscopic methods by Acid.
  • the hydrogen peroxide produced is measured by reflectance spectroscopic methods by its reaction with various dyes, in the presence of the enzyme peroxidase, to produce a color that is monitored.
  • the present invention addresses the concerns of the physician by providing enzymatic amperometry methods and apparatus for monitoring compounds within whole blood, serum, and other body fluids.
  • Enzymatic amperometry provides several advantages for controlling or eliminating operator dependant techniques as well as providing a greater linear dynamic range. A system based on this type of method could address the concerns of the physician hesitant to recommend self-testing for his patients.
  • Enzymatic amperometry methods have been applied to the laboratory based measurement of a number of analytes including glucose, blood urea nitrogen, and lactate.
  • the electrodes in these systems consist of bulk metal wires, cylinders or disks imbedded in an insulating material. The fabrication process results in individualistic characteristics for each electrode necessitating calibration of each sensor. These electrodes are also too costly for disposable use, necessitating meticulous attention to electrode maintenance for continued reliable use.
  • the present invention addresses these requirements by providing miniaturized disposable electroanalytic sample cells for precise micro-aliquot sampling, a self-contained, automatic means for measuring the electrochemical reduction of the sample, and a method for using the cell and apparatus according to the present invention.
  • the disposable cells according to the present invention are preferably laminated layers of metallized plastic and nonconducting material.
  • the metallized layers provide the working and reference electrodes, the areas of which are reproducibly defined by the lamination process.
  • An opening through these layers is designed to provide the sample-containing area or cell for the precise measurement of the sample. The insertion of the cell into the apparatus according to the present invention, automatically initiates the measurement cycle.
  • a presently preferred embodiment of the invention which involves a two-step reaction sequence utilizing a chemical oxidation step using other oxidants than oxygen, and an electrochemical reduction step suitable for quantifying the reaction product of the first step.
  • One advantage to utilizing an oxidant other than dioxygen for the direct determination of an analyte is that such other oxidants may be prepositioned in the sensor in a large excess of the analyte and thus ensure that the oxidant is not the limiting reagent (with dioxygen, there is normally insufficient oxidant initially present in the sensor solution for a quantitative conversion of the analyte).
  • oxidation reaction a sample containing glucose, for example, is converted to gluconic acid and a reduction product of the oxidant.
  • This chemical oxidation reaction has been found to precede to completion in the presence of an enzyme, glucose oxidase, which is highly specific for the substrate B-D-glucose, and catalyzes oxidations with single and double electron acceptors. It has been found, however, that the oxidation process does not proceed beyond the formation of gluconic acid, thus making this reaction particularly suited for the electrochemical measurement of glucose.
  • oxidations with one electron acceptor using ferrocyanide, ferricinum, cobalt (III) orthophenanthroline, and cobalt (III) dipyridyl are preferred.
  • Benzoquinone is a two electron acceptor which also provides excellent electro-oxidation characteristics for amperometric quantitation.
  • Amperometric determination of glucose for example, in accordance with the present invention utilizes Cottrell current micro-chronoamperometry in which glucose plus an oxidized electron acceptor produces gluconic acid and a reduced acceptor. This determination involves a preceding chemical oxidation step catalyzed by a bi-substrate bi-product enzymatic mechanism as will become apparent throughout this specification.
  • i denotes current
  • nF is the number of coulombs per mole
  • A is the area of the electrode
  • D is the diffusion coefficient of the reduced form of the reagent
  • t is the preset time at which the current is measured
  • C is the concentration of the metabolite.
  • the method and apparatus of the present invention permit, in preferred embodiments, direct measurements of blood glucose, cholesterol and the like. Furthermore, the sample cell according to the present invention, provides the testing of controlled volumes of blood without premeasuring. Insertion of the sample cell into the apparatus thus permits automatic functioning and timing of the reaction allowing for patient self-testing with a very high degree of precision and accuracy.
  • the method and apparatus according to this embodiment are designed to provide clinical self-monitoring of blood glucose levels by a diabetic patient.
  • the sample cell of the invention is used to control the sampling volume and reaction media and acts as the electrochemical sensor.
  • benzoquinone is used as the electron acceptor.
  • the basic chemical binary reaction utilized by the method according to one preferred embodiment of the present invention is:
  • the first reaction is an oxidation reaction which proceeds to completion in the presence of the enzyme glucose oxidase.
  • Electrochemical oxidation takes place in the second part of the reaction and provides the means for quantifying the amount of hydroquinone produced in the oxidation reaction. This holds true whether catalytic oxidation is conducted with two-electron acceptors or one electron acceptor such as ferricyanide [wherein the redox couple would be Fe(CN) 6 ⁇ 3 /Fe(CN) 6 ⁇ 4 ], ferricinium, cobalt III orthophenanthroline and cobalt (III) dipyridyl.
  • Catalytic oxidation by glucose oxidase is highly specific for B-D-glucose, but is nonselective as to the oxidant. It has now been discovered that the preferred oxidants described above have sufficiently positive potentials to convert substantially all of the B-D-glucose to gluconic acid. Furthermore, this system provides a means by which amounts as small as 1 mg of glucose (in the preferred embodiment) to 1000 mg of glucose can be measured per deciliter of sample—results which have not previously been obtained using other glucose self-testing systems.
  • the sensors containing the chemistry to perform the desired determination are used with a portable meter for self-testing systems.
  • the sensor is inserted into the meter, which turns the meter on and initiates a wait for the application of the sample.
  • the meter recognizes sample application by the sudden charging current flow that occurs when the electrodes and the overlaying reagent layer are initially wetted by the sample fluid.
  • the meter begins the reaction incubation step (the length of which is chemistry dependent) to allow the enzymatic reaction to reach completion. This period is on the order of 15 to 90 seconds for glucose, with incubation times of 20 to 45 seconds preferred.
  • the instrument then imposes a known potential across the electrodes and measures the resulting diffusion limited (i.e., Cottrell) current at specific time points during the Cottrell current decay.
  • Current measurements can be made in the range of 2 to 30 seconds following potential application with measurement times of 10 to 20 seconds preferred. These current values are then used to calculate the analyte concentration which is then displayed. The meter will then wait for either the user to remove the sensor or for a predetermined period before shutting itself down.
  • FIG. 13 represents a schematic circuit diagram which can be employed in producing a preferred embodiment of the invention for taking multiple current measurements.
  • the present invention provides for a measurement system that eliminates several of the critical operator dependant variables that adversely affect the accuracy and reliability and provides for a greater dynamic range than other self-testing systems.
  • FIG. 1 is an exploded view of a portable testing apparatus according to the present invention
  • FIG. 2 is a plan view of the sampling cell of the present invention.
  • FIG. 3 is an exploded view of the sample cell shown in FIG. 2;
  • FIG. 4 is an exploded view of another embodiment of a sample cell according to the invention.
  • FIG. 5 is a plan view of the cell shown in FIG. 4;
  • FIG. 6 is a graph showing current as a function of glucose concentration
  • FIG. 7 is a graphical presentation of Cottrell current as a function of glucose concentration.
  • FIG. 8 is a presently preferred circuit diagram of an electrical circuit for use in the apparatus shown in FIG. 1.
  • FIG. 9 is a preferred embodiment of the electrochemical cell of the invention wherein the reference electrode area is greater than the working electrode area.
  • FIG. 10 is a preferred embodiment of the invention wherein the two electrodes are co- planar, equal size, and preferably the same noble metal.
  • FIG. 11 is a graph showing multiple current measurements of the present invention.
  • FIG. 12 is a graph correlating measured current to glucose concentration for the curves of FIG. 11.
  • FIG. 13 is a schematic circuit diagram depicting a preferred embodiment of the invention.
  • a portable electrochemical testing apparatus 10 for use in patient self-testing, such as, for example, for blood glucose levels.
  • Apparatus 10 comprises a front and back housing 11 and 12 , respectively, a front panel 13 and a circuit board 15 .
  • Front panel 13 includes graphic display panels 16 for providing information and instructions to the patient, and direct read-out of the test results.
  • a start button 18 is provided to initiate an analysis, it is preferred that the system begin operation when a sample cell 20 (FIG. 2) is inserted into the window 19 of the apparatus.
  • sample cell 20 is a metallized plastic substrate having a specifically-sized opening 21 which defines a volumetric well 21 , when the cell is assembled, for containing a reagent pad and the blood to be analyzed.
  • Cell 20 comprises a first substrate 22 and a second substrate 23 which may be preferably made from styrene or other substantially non-conducting plastic, such as polyimide, polyethylene, etc.
  • styrene polyimide
  • Polyimide has proven particularly preferred because the metal adheres well to it, and the electrodes may be more readily slitted to the desired width.
  • Polyimide sold under the trademark KAPTON, and available from DuPont has proven particularly advantageous.
  • Reference electrode 24 Positioned on second substrate 23 is reference electrode 24 .
  • Reference electrode 24 may be preferably manufactured, for example, by vapor depositing or “sputtering” the electrode onto a substrate made from a material such as the polyimide Kapton.
  • reference electrode 24 is a silver—silver chloride electrode. This electrode can be produced by first depositing a silver chloride layer on a silver layer by either chemical or electrochemical means before the substrate is used to construct the cells. The silver chloride layer may even be generated in-situ on a silver electrode when the reagent layer contains certain of the oxidants, such as ferricyanide, and chloride as shown in the following reactions:
  • the silver—silver chloride electrode can be produced by depositing a layer of silver oxide (by reactive sputtering) onto the silver film. The silver oxide layer is then converted in-situ at the time of testing to silver chloride according to the reaction:
  • the reference electrode may also be of the type generally known as a “pseudo”reference electrode which relies upon the large excess of the oxidizing species to establish a known potential at a noble metal electrode.
  • a “pseudo”reference electrode which relies upon the large excess of the oxidizing species to establish a known potential at a noble metal electrode.
  • two electrodes of the same noble metal or carbon are used, however one is generally of greater surface area and is used as the reference electrode. The large excess of the oxidized species and the larger surface area of the reference resists a shift of the potential of the reference electrode.
  • the primary requirement for the pseudo-reference (as is also the case with traditional reference electrodes) is that it should be able to supply the necessary current (in opposition to the current flow at the working electrode) without significant shift in its potential.
  • Providing a larger surface area for the reference electrode than for the working electrode is one way to accomplish this.
  • high concentration of the oxidant are utilized and/or the range of currents is kept relatively low, e.g., less than about 20 to 40 milliamps/cm 2 , with 0.1M ferricyanide as the oxidant, it is possible to reduce the ratio of the reference to working electrode to 1:1 or even less.
  • the use of equal size electrodes offers some advantage in terms of manufacture but with potentially a limitation to the upper range.
  • a large excess of oxidized species i.e., wherein the oxidized form of the redox mediator (i.e., ferricyanide) is present in the reagent layer in sufficient excess to insure that the diffusion limited electrooxidation of the redox mediator at the working electrode surface is the principal limiter of current flow through the cell and resists a shift of the potential of the second electrode (i.e., pseudo-reference) vis-a-vis the first (i.e., working) electrode.
  • the second electrode i.e., pseudo-reference
  • the two-electrode system uses same size, same metal electrodes.
  • noble metals such as palladium are used.
  • a potential of +0.30 volts applied between the electrodes has proven effective when ferricyanide is the oxidant.
  • Acceptable same-size palladium vs. palladium coplanar-electrodes may be produced from metalized plastic slitted by a high performance slitter such as Metlon Corp., 133 Francis Avenue, Cranston, R.I. 02910.
  • a 1st is the area of the first (i.e., working) electrode
  • C 1st is the concentration of the reduced form of oxidant in the solution in the reagent layer at time zero (the instant the potential is applied)
  • a 2nd is the area of the second (i.e., reference or counter) electrode
  • C 2nd is the concentration of reduced form of the oxidant generated at or by the second electrode at time zero (the instant the potential is applied).
  • the second electrode acts to balance current flow.
  • the smaller the second electrode the higher the concentration of the reduced oxidant produced at the surface of that electrode; the higher the concentration, the greater the diffusion gradient and the greater the potential for the reduced oxidant produced at the second electrode to diffuse towards the working electrode and cause an undesired additional current flow, resulting in a departure from expected Cottrell current flow for the system.
  • First and second electrodes 424 , 426 must be spaced apart by a distance d (FIG. 10) sufficient to avoid this departure from expected Cottrell current.
  • a distance d of at least 0.1 mm, preferably greater than 0.1 mm, has proven effective at current flows of 0-50 microamps and about 5 mm 2 working electrode area.
  • d is about 1-2 mm
  • a 1st and A 2nd are both about 5 mm 2
  • current flow is about 0-100 microamps, with measurement time of less than 30 seconds.
  • the maximum spacing for d is dictated by the conductivity of the solution, which effects to the actual voltage at the electrodes (obviated in 3-electrode systems). Practical considerations, however, dictate that the spacing d be as small as technically feasible to mimnmize substrate, reagent, and sample size requirements. Ideally, the preferred sample is the size of a drop of blood of less than 20 microliters, which must bridge the electrodes and wet the reagent layer. As a practical matter, the spacing d should not exceed about 1 cm because of the difficulty of bridging such a gap with a drop of blood of this size and substantially instantaneously spreading that drop of blood across the reagent layer.
  • sample i.e., blood
  • wicking layer is helpful in this regard.
  • a two mm 2 palladium indicator electrode was referenced to a two mm 2 Ag/Ag 2 O electrode and the electrodes were spaced apart by a 2 mm gap. Measurements were taken from sample cells including the reagents described herein, including an analyte (i.e., glucose) the oxidized form of a redox mediator (i.e., ferricyanide), an enzyme (i.e., glucose oxidase), and a buffer (i.e., phosphate).
  • analyte i.e., glucose
  • a redox mediator i.e., ferricyanide
  • an enzyme i.e., glucose oxidase
  • a buffer i.e., phosphate
  • the oxidized form of the redox mediator is present in sufficient quantity to insure that the counter electrode current, i.e., that produced at the reference electrode, is not limiting as a result of conversion to the reduced form of the redox mediator at the working electrode surface.
  • a consentration series for ferrocyanide from 0 through 30 millimolar was similarly obtained.
  • a plot of the currents at 10 seconds vs. ferrocyanide concentration indicated a linearly increasing current with concentration through 25 millimolar (approximately 360 mg/dl glucose). Similar results can be obtained when both same-size electrodes are the same noble metal, such as palladium.
  • the buffer used in the reagent layer is preferably non-reactive with respect to the reduced and oxidized form of the redox mediator (i.e., has a higher oxidation potential).
  • Phosphate buffer has proven effective in this regard, although other suitable buffers would, of course, now be readily apparent to those of ordinary skill in the art.
  • Indicator or working electrode 26 can be either a strip of platinum, gold, or palladium metallized plastic positioned on reference electrode 24 , or, alternately, as showned in FIG. 10, the working electrode 426 and reference electrode 424 are laminated between an upper 422 and lower 423 non-conducting (i.e. electrically insulating) material, such as polyethylene or polystyrene.
  • sample cell 20 is prepared by sandwiching or laminating the electrodes between the substrate to form a composite unit.
  • other methods of applying the metal or other electrically conducting material such as, without limitation, silk screening, vapor deposition, electrolysis, adhesion, etc., may also be employed.
  • any combination of suitable electrode pairs may be used. Names other than “working” vs. “reference” electrodes which have been interchangeably used in electrochemical applications include, “working” v.s. “counter” electrodes, “excitation” v. “source” electrodes, or three electrode systems having a “working” electrode, a “reference”electrode, and an “auxiliary” electrode.
  • the auxiliary electrode completes the circuit, allowing current to flow through the cell, while the reference electrode maintains a constant interfacial potential difference regardless of the current.
  • the second electrode serves both the finction of an auxiliary and reference electrode.
  • the electrochemistry of interest in the present invention occurs at a first electrode (i.e., working) and a second electrode (i.e., reference or counter) acts to counter balance current flow (i.e., provide opposing current flow to the first electrode) and fix the operating potential of the system.
  • first substrate 22 is of a slightly shorter length so as to expose an end portion 27 of electrodes 24 and 26 and allow for electrical contact with the testing circuit contained in the apparatus.
  • cell 20 is pushed into window 19 of the front panel to initiate testing.
  • a reagent may be applied to well 21 , or, preferably, a pad of dry reagent is positioned therein and a sample (drop) of blood is placed into the well 21 containing the reagent.
  • sample cell 120 is shown having first 122 and second 123 substrates.
  • Reference electrode 124 and working electrode 126 are laminated between substrates 122 and 123 . Opening 121 is dimensioned to contain the sample for testing.
  • End 130 (FIG. 5) is designed to be inserted into the apparatus, and electrical contact is made with the respective electrodes through cut-outs 131 and 132 on the cell.
  • Reference electrode 124 also includes cut out 133 to permit electrical contact with working electrode 126 .
  • the sample cell according to the present invention is positioned through window 19 (FIG. 1) to initiate the testing procedure.
  • a potential is applied at portion 27 (FIG. 2) of the sample cell across electrodes 24 and 26 to detect the presence of the sample.
  • the potential is removed and the incubation period initiated.
  • a vibrator means 31 may be activated to provide agitation of the reagents in order to enhance dissolution (an incubation period of 20 to 45 seconds is conveniently used for the determination of glucose and no vibration is normally required).
  • An electrical potential is next applied at portion 27 of the sample cell to electrodes 24 and 26 and the current through the sample is measured and displayed on display 16 .
  • the needed chemistry for the self testing systems is incorporated into a dry reagent layer that is positioned onto the disposable cell creating a complete sensor for the intended analyte.
  • the disposable electrochemical cell is constructed by the lamination of metallized plastics and nonconducting materials in such a way that there is a precisely defined working electrode area.
  • the reagent layer is either directly coated onto the cell or preferably incorporated (coated) into a supporting matrix such as filter paper, membrane filter, woven fabric or non-woven fabric, which is then placed into the cell, substantially covering the electrode surfaces exposed by the cutout portion or window of the electrically insulating upper laminate.
  • the coating formulation generally includes a binder such as gelatin, carrageenan, methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc., that acts to delay the dissolution of the reagents until the reagent layer has absorbed most of the fluid from the sample.
  • concentration of the binder is generally on the order of 0.1 to 10% with 1-4% preferred.
  • the reagent layer imbibes a fixed amount of the sample fluid when it is applied to the surface of the layer thus eliminating any need for premeasurement of sample volume. Furthermore, by virtue of measuring current flow rather than reflected light, there is no need to remove the blood from the surface of the reagent layer prior to measurement as there is with reflectance spectroscopy systems. While the fluid sample could be applied directly to the surface of the reagent layer, to facilitate spread of blood across the entire surface of the reagent layer the sensor preferably includes a dispersing spreading or wicking layer. This layer, generally a nonwoven fabric or adsorbent paper, is positioned over the reagent layer and acts to rapidly distribute the blood over the reagent layer. In some applications this dispersing layer could incorporate additional reagents.
  • the enzyme i.e., glucose oxidase
  • the enzyme is sufficient in type and amount to catalyze the reaction (i.e., receive at least one electron from the reaction) involving the enzyme, the analyte (i.e., glucose) and the oxidized form of the redox mediator (i.e., ferricyanide).
  • the redox mediator i.e., ferricyanide
  • surfactant can also be used in the reagent layer to promote wetting of the reagent by the sample containing the analyte.
  • Circuit 15 includes a microprocessor and LCD panel 16 .
  • the working and reference electrodes on the sample cell 20 make contact at contacts W (working electrode) and R (reference electrode), respectively.
  • Voltage reference 41 is connected to battery 42 through analogue power switchb 43 .
  • Current from electrodes W and R is converted to a voltage by op amp 45 . That voltage is converted into a digital signal (frequency) by a voltage to frequency converter 46 electrically connected to the microprocessor 48 .
  • the microprocessor 48 controls the timing of the signals. Measurement of current flow is converted by microprocessor 48 to equivalent glucose, cholesterol or other substance concentrations.
  • Other circuits within the skills of a practiced engineer can now be utilized to obtain the advantages of the present invention.
  • cell 400 consists of coplanar first (i.e., working) 426 and second (i.e., reference) 424 electrodes laminated between an upper 422 and lower 423 nonconducting (i.e., electrically insulating) material. Lamination is on an adhesive layer 425 .
  • the upper material 422 includes a die cut opening 428 which, along with the width of the working electrode material defines the working electrode area and provides (with an overlapping reagent layer not depicted) the sampling port of the cell.
  • this die-cut opening is rectangular or square, which has proven advantageous from the standpoint of reproduceability, as such openings are more readily centered over the co-planar electrodes than circular openings.
  • At one end of cell 400 is an open area 427 similar to end position 27 of FIG. 2.
  • the opening 428 insures that equal surface areas of the first and second electrodes are exposed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a novel method and apparatus for the amperometric determination of an analyte, and in particular, to an apparatus for amperometric analysis utilizing a novel disposable electroanalytical cell for the quantitative determination of biologically important compounds from body fluids.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a disposable electro-analytical cell and a method and apparatus for quantitatively determining the presence of biologically important compounds such as glucose; hormones, therapeutic drugs and the like from body fluids. [0001]
  • Although the present invention has broad applications, for purposes of illustration of the invention specific emphasis will be placed upon its application in quantitatively determining the presence of a biologically important compound—glucose. [0002]
  • With Respect To Glucose [0003]
  • Diabetes, and specifically diabetes mellitus, is a metabolic disease characterized by deficient insulin production by the pancreas which results in abnormal levels of blood glucose. Although this disease afflicts only approximately 4% of the population in the United States, it is the third leading cause of death following heart disease and cancer. With proper maintenance of the patient's blood sugar through daily injection of insulin, and strict control of dietary intake, the prognosis for diabetics is excellent. The blood glucose levels must, however, be closely followed in the patient either by clinical laboratory analysis or by daily analyses which the patient can conduct using relatively simple, non-technical, methods. [0004]
  • At present, current technology for monitoring blood glucose is based upon visual or instrumental determination of color change produced by enzymatic reactions on a dry reagent pad on a small plastic strip. These calorimetric methods, which utilize the natural oxidant of glucose to gluconic acid, specifically oxygen, are based upon the reactions: [0005]
  • B-D-Glucose+O2+H2O→D-Gluconic Acid+H2O2
  • H2O2+Reagent→H2O+color
  • Wherein glucose oxidase catalyzes the conversion of B-D Glucose to D-Gluconic Acid. The hydrogen peroxide produced is measured by reflectance spectroscopic methods by Acid. The hydrogen peroxide produced is measured by reflectance spectroscopic methods by its reaction with various dyes, in the presence of the enzyme peroxidase, to produce a color that is monitored. [0006]
  • While relatively easy to use, these tests require consistent user technique in order to yield reproducible results. For example, these tests require the removal of blood from a reagent pad at specified and critical time intervals. After the time interval, excess blood must be removed by washing and blotting, or by blotting alone, since the color measurement is taken at the top surface of the reagent pad. Color development is either read immediately or after a specified time interval. [0007]
  • These steps are dependent upon good and consistent operating technique requiring strict attention to timing. Moreover, even utilizing good operating technique, calorimetric methods for determining glucose, for example, have been shown to have poor precision and accuracy, particularly in the hypoglycemic range. Furthermore, instruments used for the quantitative calorimetric measurement vary widely in their calibration methods: some provide no user calibration while others provide secondary standards. [0008]
  • Because of the general lack of precision and standardization of the various methods and apparatus presently available to test for biologically important compounds in body fluids, some physicians are hesitant to use such equipment for monitoring levels or dosage. They are particularly hesitant in recommending such methods for use by the patients themselves. Accordingly, it is desirable to have a method and apparatus which will permit not only physician but patient self-testing of such compounds with greater reliability. [0009]
  • The present invention addresses the concerns of the physician by providing enzymatic amperometry methods and apparatus for monitoring compounds within whole blood, serum, and other body fluids. Enzymatic amperometry provides several advantages for controlling or eliminating operator dependant techniques as well as providing a greater linear dynamic range. A system based on this type of method could address the concerns of the physician hesitant to recommend self-testing for his patients. [0010]
  • Enzymatic amperometry methods have been applied to the laboratory based measurement of a number of analytes including glucose, blood urea nitrogen, and lactate. Traditionally the electrodes in these systems consist of bulk metal wires, cylinders or disks imbedded in an insulating material. The fabrication process results in individualistic characteristics for each electrode necessitating calibration of each sensor. These electrodes are also too costly for disposable use, necessitating meticulous attention to electrode maintenance for continued reliable use. This maintenance is not likely to be performed properly by untrained personnel (such as patients); therefore, to be successful, an enzyme arnperometry method intended for self-testing (or non-traditional site testing) must be based on a disposable sensor that can be produced in a manner that allows it to give reproducible output from sensor to sensor and at a cost well below that of traditional electrodes. [0011]
  • The present invention addresses these requirements by providing miniaturized disposable electroanalytic sample cells for precise micro-aliquot sampling, a self-contained, automatic means for measuring the electrochemical reduction of the sample, and a method for using the cell and apparatus according to the present invention. [0012]
  • The disposable cells according to the present invention are preferably laminated layers of metallized plastic and nonconducting material. The metallized layers provide the working and reference electrodes, the areas of which are reproducibly defined by the lamination process. An opening through these layers is designed to provide the sample-containing area or cell for the precise measurement of the sample. The insertion of the cell into the apparatus according to the present invention, automatically initiates the measurement cycle. [0013]
  • To better understand the process of measurement, a presently preferred embodiment of the invention is described which involves a two-step reaction sequence utilizing a chemical oxidation step using other oxidants than oxygen, and an electrochemical reduction step suitable for quantifying the reaction product of the first step. One advantage to utilizing an oxidant other than dioxygen for the direct determination of an analyte is that such other oxidants may be prepositioned in the sensor in a large excess of the analyte and thus ensure that the oxidant is not the limiting reagent (with dioxygen, there is normally insufficient oxidant initially present in the sensor solution for a quantitative conversion of the analyte). [0014]
  • In the oxidation reaction, a sample containing glucose, for example, is converted to gluconic acid and a reduction product of the oxidant. This chemical oxidation reaction has been found to precede to completion in the presence of an enzyme, glucose oxidase, which is highly specific for the substrate B-D-glucose, and catalyzes oxidations with single and double electron acceptors. It has been found, however, that the oxidation process does not proceed beyond the formation of gluconic acid, thus making this reaction particularly suited for the electrochemical measurement of glucose. [0015]
  • In a presently preferred embodiment, oxidations with one electron acceptor using ferrocyanide, ferricinum, cobalt (III) orthophenanthroline, and cobalt (III) dipyridyl are preferred. Benzoquinone is a two electron acceptor which also provides excellent electro-oxidation characteristics for amperometric quantitation. [0016]
  • Amperometric determination of glucose, for example, in accordance with the present invention utilizes Cottrell current micro-chronoamperometry in which glucose plus an oxidized electron acceptor produces gluconic acid and a reduced acceptor. This determination involves a preceding chemical oxidation step catalyzed by a bi-substrate bi-product enzymatic mechanism as will become apparent throughout this specification. [0017]
  • In this method of quantification, the measurement of a diffusion controlled current at one or more accurately specified times (e.g., 5, 10, or 15 seconds) after the instant of application of a potential has the applicable equation for amperometry at a controlled potential (E=constant) of: [0018] i COTTRELL at i > 0 = ( nFA ( Dt ) ) - 0.5 · C analyte att = 0
    Figure US20030159944A1-20030828-M00001
  • which may also be expressed as: [0019]
  • i(t)=nFACmetabolite(D)0.5(πt)−0.5
  • where i denotes current, nF is the number of coulombs per mole, A is the area of the electrode, D is the diffusion coefficient of the reduced form of the reagent, t is the preset time at which the current is measured, and C is the concentration of the metabolite. Measurements by the method according to the present invention of the current due to the reoxidation of the acceptors were found to be proportional to the glucose concentration in the sample. [0020]
  • The method and apparatus of the present invention permit, in preferred embodiments, direct measurements of blood glucose, cholesterol and the like. Furthermore, the sample cell according to the present invention, provides the testing of controlled volumes of blood without premeasuring. Insertion of the sample cell into the apparatus thus permits automatic functioning and timing of the reaction allowing for patient self-testing with a very high degree of precision and accuracy. [0021]
  • One of many of the presently preferred embodiments of the invention for use in measuring B-D glucose is described in detail to better understand the nature and scope of the invention. In particular, the method and apparatus according to this embodiment are designed to provide clinical self-monitoring of blood glucose levels by a diabetic patient. The sample cell of the invention is used to control the sampling volume and reaction media and acts as the electrochemical sensor. In this described embodiment, benzoquinone is used as the electron acceptor. [0022]
  • The basic chemical binary reaction utilized by the method according to one preferred embodiment of the present invention is: [0023]
  • B-D-glucose+Benzoquinone+H2O→Gluconic Acid→Hydroquinone
  • Hydroquinone→benzoquinone-2e-+2H+.
  • The first reaction is an oxidation reaction which proceeds to completion in the presence of the enzyme glucose oxidase. Electrochemical oxidation takes place in the second part of the reaction and provides the means for quantifying the amount of hydroquinone produced in the oxidation reaction. This holds true whether catalytic oxidation is conducted with two-electron acceptors or one electron acceptor such as ferricyanide [wherein the redox couple would be Fe(CN)[0024] 6 −3/Fe(CN)6 −4], ferricinium, cobalt III orthophenanthroline and cobalt (III) dipyridyl.
  • Catalytic oxidation by glucose oxidase is highly specific for B-D-glucose, but is nonselective as to the oxidant. It has now been discovered that the preferred oxidants described above have sufficiently positive potentials to convert substantially all of the B-D-glucose to gluconic acid. Furthermore, this system provides a means by which amounts as small as 1 mg of glucose (in the preferred embodiment) to 1000 mg of glucose can be measured per deciliter of sample—results which have not previously been obtained using other glucose self-testing systems. [0025]
  • The sensors containing the chemistry to perform the desired determination, constructed in accordance with the present invention, are used with a portable meter for self-testing systems. In use, the sensor is inserted into the meter, which turns the meter on and initiates a wait for the application of the sample. The meter recognizes sample application by the sudden charging current flow that occurs when the electrodes and the overlaying reagent layer are initially wetted by the sample fluid. Once the sample application is detected, the meter begins the reaction incubation step (the length of which is chemistry dependent) to allow the enzymatic reaction to reach completion. This period is on the order of 15 to 90 seconds for glucose, with incubation times of 20 to 45 seconds preferred. Following the incubation period, the instrument then imposes a known potential across the electrodes and measures the resulting diffusion limited (i.e., Cottrell) current at specific time points during the Cottrell current decay. Current measurements can be made in the range of 2 to 30 seconds following potential application with measurement times of 10 to 20 seconds preferred. These current values are then used to calculate the analyte concentration which is then displayed. The meter will then wait for either the user to remove the sensor or for a predetermined period before shutting itself down. [0026]
  • Due to the nature of the Cottrell current, it is possible to develop a calibration curve at more than one time point following application of the potential in order to verify that the measurement is being accurately made. Results can then be calculated at the different time points and compared. This is illustrated schematically in FIGS. 11 and 12; which indicate expected, or “normal” Cottrell curves, A, B, C, D, for various glucose concentrations and an abnormal curve E, showing divergence from expected curve D as indicated by the multiple current readings. In a system that is operating correctly, the results should agree within reasonable limits. The exact range of acceptable difference between the expected and measured currents depends on a number of compromises but would generally be in the range of 1-10%. Results outside of the acceptable limits would indicate some problem with the system. For instance, incomplete wetting of the reagent (i.e., too small of a drop of blood) would result in failure to follow the Cottrell curve decay and result in a higher value being calculated at subsequent measurement points than would have been expected for Cottrell current curve delay. FIG. 13 represents a schematic circuit diagram which can be employed in producing a preferred embodiment of the invention for taking multiple current measurements. [0027]
  • The present invention provides for a measurement system that eliminates several of the critical operator dependant variables that adversely affect the accuracy and reliability and provides for a greater dynamic range than other self-testing systems.[0028]
  • These and other advantages of the present invention will become apparent from a perusal of the following detailed description of one embodiment presently preferred for measuring glucose and other analytes which is to be taken in conjunction with the accompanying drawings in which like numerals indicate like components and in which: [0029]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is an exploded view of a portable testing apparatus according to the present invention; [0030]
  • FIG. 2 is a plan view of the sampling cell of the present invention; [0031]
  • FIG. 3 is an exploded view of the sample cell shown in FIG. 2; [0032]
  • FIG. 4 is an exploded view of another embodiment of a sample cell according to the invention; [0033]
  • FIG. 5 is a plan view of the cell shown in FIG. 4; [0034]
  • FIG. 6 is a graph showing current as a function of glucose concentration; [0035]
  • FIG. 7 is a graphical presentation of Cottrell current as a function of glucose concentration; and [0036]
  • FIG. 8 is a presently preferred circuit diagram of an electrical circuit for use in the apparatus shown in FIG. 1. [0037]
  • FIG. 9 is a preferred embodiment of the electrochemical cell of the invention wherein the reference electrode area is greater than the working electrode area. [0038]
  • FIG. 10 is a preferred embodiment of the invention wherein the two electrodes are co- planar, equal size, and preferably the same noble metal. [0039]
  • FIG. 11 is a graph showing multiple current measurements of the present invention. [0040]
  • FIG. 12 is a graph correlating measured current to glucose concentration for the curves of FIG. 11. [0041]
  • FIG. 13 is a schematic circuit diagram depicting a preferred embodiment of the invention.[0042]
  • With specific reference to FIG. 1, a portable [0043] electrochemical testing apparatus 10 is shown for use in patient self-testing, such as, for example, for blood glucose levels. Apparatus 10 comprises a front and back housing 11 and 12, respectively, a front panel 13 and a circuit board 15. Front panel 13 includes graphic display panels 16 for providing information and instructions to the patient, and direct read-out of the test results. While a start button 18 is provided to initiate an analysis, it is preferred that the system begin operation when a sample cell 20 (FIG. 2) is inserted into the window 19 of the apparatus.
  • With reference to FIGS. 2 and 3, [0044] sample cell 20 is a metallized plastic substrate having a specifically-sized opening 21 which defines a volumetric well 21, when the cell is assembled, for containing a reagent pad and the blood to be analyzed. Cell 20 comprises a first substrate 22 and a second substrate 23 which may be preferably made from styrene or other substantially non-conducting plastic, such as polyimide, polyethylene, etc. Polyimide has proven particularly preferred because the metal adheres well to it, and the electrodes may be more readily slitted to the desired width. Polyimide sold under the trademark KAPTON, and available from DuPont, has proven particularly advantageous.
  • Positioned on [0045] second substrate 23 is reference electrode 24. Reference electrode 24 may be preferably manufactured, for example, by vapor depositing or “sputtering” the electrode onto a substrate made from a material such as the polyimide Kapton. In one preferred embodiment, reference electrode 24 is a silver—silver chloride electrode. This electrode can be produced by first depositing a silver chloride layer on a silver layer by either chemical or electrochemical means before the substrate is used to construct the cells. The silver chloride layer may even be generated in-situ on a silver electrode when the reagent layer contains certain of the oxidants, such as ferricyanide, and chloride as shown in the following reactions:
  • Ag+Ox→Ag+Red
  • Ag+Cl→AgCl
  • Alternatively the silver—silver chloride electrode can be produced by depositing a layer of silver oxide (by reactive sputtering) onto the silver film. The silver oxide layer is then converted in-situ at the time of testing to silver chloride according to the reaction: [0046]
  • Ag2O+H2O+2Cl→2AgCl+2(OH)
  • when the sensor is wetted by the sample fluid and reconstitutes the chloride containing reagent layer. The silver electrode is thus coated with a layer containing silver chloride. [0047]
  • The reference electrode may also be of the type generally known as a “pseudo”reference electrode which relies upon the large excess of the oxidizing species to establish a known potential at a noble metal electrode. In a preferred embodiment, two electrodes of the same noble metal or carbon are used, however one is generally of greater surface area and is used as the reference electrode. The large excess of the oxidized species and the larger surface area of the reference resists a shift of the potential of the reference electrode. [0048]
  • The primary requirement for the pseudo-reference (as is also the case with traditional reference electrodes) is that it should be able to supply the necessary current (in opposition to the current flow at the working electrode) without significant shift in its potential. Providing a larger surface area for the reference electrode than for the working electrode is one way to accomplish this. When high concentration of the oxidant are utilized and/or the range of currents is kept relatively low, e.g., less than about 20 to 40 milliamps/cm[0049] 2, with 0.1M ferricyanide as the oxidant, it is possible to reduce the ratio of the reference to working electrode to 1:1 or even less. The use of equal size electrodes offers some advantage in terms of manufacture but with potentially a limitation to the upper range.
  • In the case of same size (i.e., same surface area) electrodes, a large excess of oxidized species (i.e., wherein the oxidized form of the redox mediator (i.e., ferricyanide) is present in the reagent layer in sufficient excess to insure that the diffusion limited electrooxidation of the redox mediator at the working electrode surface is the principal limiter of current flow through the cell and resists a shift of the potential of the second electrode (i.e., pseudo-reference) vis-a-vis the first (i.e., working) electrode. [0050]
  • In a highly preferred embodiment of the invention, the two-electrode system uses same size, same metal electrodes. Preferably noble metals, such as palladium are used. In this palladium vs. palladium embodiment, a potential of +0.30 volts applied between the electrodes has proven effective when ferricyanide is the oxidant. Acceptable same-size palladium vs. palladium coplanar-electrodes may be produced from metalized plastic slitted by a high performance slitter such as Metlon Corp., 133 Francis Avenue, Cranston, R.I. 02910. [0051]
  • In the pseudo-reference instance, care must be exercised in the spacing of the electrodes. This is due to the fact that as the second electrode functions to provide the balancing current, it is actually producing the reduced form of the oxidant (redox mediator). If the electrodes are spaced too closely together, the reduced form produced at the second electrode can diffuse toward the working electrode, where it would then be re-oxidized, adding to the current flow due to the oxidation of the reduced form produced by the enzymatic reaction. The net effect would be a departure from the expected Cottrell current decay curve illustrated in FIGS. 7 and 11. [0052]
  • This problem is potentially aggravated when the size of the second electrode, vis-a-vis the first, is reduced, such as in the case of same-size electrodes or when the second electrode is smaller than the working electrode. This is due to the higher effective concentration of reduced oxidant produced over the surface of the second electrode. This can be shown by the following analysis. The current flow at the two electrodes can be represented by the Cottrell equation. For the first electrode, that is: [0053] i t = nFA 1 st DC 1 st π Dt
    Figure US20030159944A1-20030828-M00002
  • At the second electrode that is: [0054] i t = nFA 2 nd DC 2 nd π Dt
    Figure US20030159944A1-20030828-M00003
  • Since the two currents must be of the same magnitude (but opposite sign), the following is true at any given time:[0055]
  • dC1stA1st=dC2ndA2nd
  • Where A[0056] 1st is the area of the first (i.e., working) electrode, C1st is the concentration of the reduced form of oxidant in the solution in the reagent layer at time zero (the instant the potential is applied), A2nd is the area of the second (i.e., reference or counter) electrode, and C2nd is the concentration of reduced form of the oxidant generated at or by the second electrode at time zero (the instant the potential is applied).
  • Since the working electrode is poised to control the current flow, the second electrode acts to balance current flow. Thus, the smaller the second electrode, the higher the concentration of the reduced oxidant produced at the surface of that electrode; the higher the concentration, the greater the diffusion gradient and the greater the potential for the reduced oxidant produced at the second electrode to diffuse towards the working electrode and cause an undesired additional current flow, resulting in a departure from expected Cottrell current flow for the system. First and [0057] second electrodes 424, 426 must be spaced apart by a distance d (FIG. 10) sufficient to avoid this departure from expected Cottrell current. A distance d of at least 0.1 mm, preferably greater than 0.1 mm, has proven effective at current flows of 0-50 microamps and about 5 mm2 working electrode area. The higher the expected current density, the greater d must be in order to insure true Cottrell measurement. Also, if measurement times exceed about 30 seconds, it is necessary to increase the distance d. In a highly preferred embodiment of the invention, d is about 1-2 mm, A1st and A2nd are both about 5 mm2, current flow is about 0-100 microamps, with measurement time of less than 30 seconds.
  • The maximum spacing for d is dictated by the conductivity of the solution, which effects to the actual voltage at the electrodes (obviated in 3-electrode systems). Practical considerations, however, dictate that the spacing d be as small as technically feasible to mimnmize substrate, reagent, and sample size requirements. Ideally, the preferred sample is the size of a drop of blood of less than 20 microliters, which must bridge the electrodes and wet the reagent layer. As a practical matter, the spacing d should not exceed about 1 cm because of the difficulty of bridging such a gap with a drop of blood of this size and substantially instantaneously spreading that drop of blood across the reagent layer. It is important that the sample, i.e., blood, spread across the reagent layer substantially instantaneously following application of the sample to the cell, in order to avoid migration of reagents, or erosion of reagents from the site at which the drop of blood was applied. The wicking layer is helpful in this regard. [0058]
  • EXAMPLE 1
  • A two mm[0059] 2 palladium indicator electrode was referenced to a two mm2 Ag/Ag2O electrode and the electrodes were spaced apart by a 2 mm gap. Measurements were taken from sample cells including the reagents described herein, including an analyte (i.e., glucose) the oxidized form of a redox mediator (i.e., ferricyanide), an enzyme (i.e., glucose oxidase), and a buffer (i.e., phosphate). Preferably, in the case of same size, same noble metal electrodes, the oxidized form of the redox mediator is present in sufficient quantity to insure that the counter electrode current, i.e., that produced at the reference electrode, is not limiting as a result of conversion to the reduced form of the redox mediator at the working electrode surface. The data for the results, summarized in Table 1, were obtained 10 seconds after current was applied.
  • For 5 millimolar ferrocyanide corresponding to 4 millimolar glucose (72 mg/dl), an average current of 27.1 microamps was obtained. The relative standard deviation was 5.3%. For 20 millimolar ferrocyanide, an average current of 102.9 was obtained and the relative standard deviation was 3.9%. In this experiment, the volumes tested were 50 microliters, although smaller volumes such as 10 microliters could be employed if the area of the 2 mm[0060] 2 electrode strips weree decreased.
  • A consentration series for ferrocyanide from 0 through 30 millimolar was similarly obtained. A plot of the currents at 10 seconds vs. ferrocyanide concentration indicated a linearly increasing current with concentration through 25 millimolar (approximately 360 mg/dl glucose). Similar results can be obtained when both same-size electrodes are the same noble metal, such as palladium. [0061]
  • The buffer used in the reagent layer is preferably non-reactive with respect to the reduced and oxidized form of the redox mediator (i.e., has a higher oxidation potential). Phosphate buffer has proven effective in this regard, although other suitable buffers would, of course, now be readily apparent to those of ordinary skill in the art. [0062]
    Corresponding
    Cottrell Current, Glucose
    microamps, at 10 seconds Fe (CN)6 4− Concentration Concentration,
    after E is applied millimolar mg/dl
    0 0 0
    27 5 72
    58 10 144
    75 15 216
    103 20 288
    142 25 360
    136 30 432
  • Indicator or working [0063] electrode 26 can be either a strip of platinum, gold, or palladium metallized plastic positioned on reference electrode 24, or, alternately, as showned in FIG. 10, the working electrode 426 and reference electrode 424 are laminated between an upper 422 and lower 423 non-conducting (i.e. electrically insulating) material, such as polyethylene or polystyrene. Preferably, sample cell 20 is prepared by sandwiching or laminating the electrodes between the substrate to form a composite unit. Of course, other methods of applying the metal or other electrically conducting material, such as, without limitation, silk screening, vapor deposition, electrolysis, adhesion, etc., may also be employed.
  • Of course, any combination of suitable electrode pairs may be used. Names other than “working” vs. “reference” electrodes which have been interchangeably used in electrochemical applications include, “working” v.s. “counter” electrodes, “excitation” v. “source” electrodes, or three electrode systems having a “working” electrode, a “reference”electrode, and an “auxiliary” electrode. In the case of a three-electrode system, the auxiliary electrode completes the circuit, allowing current to flow through the cell, while the reference electrode maintains a constant interfacial potential difference regardless of the current. In the two electrode scenario, the second electrode serves both the finction of an auxiliary and reference electrode. Regardless of the nomenclature employed, the electrochemistry of interest in the present invention occurs at a first electrode (i.e., working) and a second electrode (i.e., reference or counter) acts to counter balance current flow (i.e., provide opposing current flow to the first electrode) and fix the operating potential of the system. [0064]
  • As shown in FIG. 2, [0065] first substrate 22 is of a slightly shorter length so as to expose an end portion 27 of electrodes 24 and 26 and allow for electrical contact with the testing circuit contained in the apparatus. In this embodiment, after a sample has been positioned within well 21, cell 20 is pushed into window 19 of the front panel to initiate testing. In this embodiment, a reagent may be applied to well 21, or, preferably, a pad of dry reagent is positioned therein and a sample (drop) of blood is placed into the well 21 containing the reagent.
  • Referring to FIGS. [0066] 4-5, alternative embodiments of sample cell 20 are shown. In FIG. 4, sample cell 120 is shown having first 122 and second 123 substrates. Reference electrode 124 and working electrode 126 are laminated between substrates 122 and 123. Opening 121 is dimensioned to contain the sample for testing. End 130 (FIG. 5) is designed to be inserted into the apparatus, and electrical contact is made with the respective electrodes through cut- outs 131 and 132 on the cell. Reference electrode 124 also includes cut out 133 to permit electrical contact with working electrode 126.
  • Referring to FIGS. 1 and 2, the sample cell according to the present invention is positioned through window [0067] 19 (FIG. 1) to initiate the testing procedure. Once inserted, a potential is applied at portion 27 (FIG. 2) of the sample cell across electrodes 24 and 26 to detect the presence of the sample. Once the sample's presence is detected, the potential is removed and the incubation period initiated. Optionally during this period, a vibrator means 31 (FIG. 1) may be activated to provide agitation of the reagents in order to enhance dissolution (an incubation period of 20 to 45 seconds is conveniently used for the determination of glucose and no vibration is normally required). An electrical potential is next applied at portion 27 of the sample cell to electrodes 24 and 26 and the current through the sample is measured and displayed on display 16.
  • To fully take advantage of the above apparatus, the needed chemistry for the self testing systems is incorporated into a dry reagent layer that is positioned onto the disposable cell creating a complete sensor for the intended analyte. The disposable electrochemical cell is constructed by the lamination of metallized plastics and nonconducting materials in such a way that there is a precisely defined working electrode area. The reagent layer is either directly coated onto the cell or preferably incorporated (coated) into a supporting matrix such as filter paper, membrane filter, woven fabric or non-woven fabric, which is then placed into the cell, substantially covering the electrode surfaces exposed by the cutout portion or window of the electrically insulating upper laminate. When a supporting matrix is used, its pore size and void volume can be adjusted to provide the desired precision and mechanical support. In general, membrane filters or nonwoven fabrics provide the best materials for the reagent layer support. Pore sizes of 0.45 to 50 um and void volumes of 50-90% are appropriate. The coating formulation generally includes a binder such as gelatin, carrageenan, methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc., that acts to delay the dissolution of the reagents until the reagent layer has absorbed most of the fluid from the sample. The concentration of the binder is generally on the order of 0.1 to 10% with 1-4% preferred. [0068]
  • The reagent layer imbibes a fixed amount of the sample fluid when it is applied to the surface of the layer thus eliminating any need for premeasurement of sample volume. Furthermore, by virtue of measuring current flow rather than reflected light, there is no need to remove the blood from the surface of the reagent layer prior to measurement as there is with reflectance spectroscopy systems. While the fluid sample could be applied directly to the surface of the reagent layer, to facilitate spread of blood across the entire surface of the reagent layer the sensor preferably includes a dispersing spreading or wicking layer. This layer, generally a nonwoven fabric or adsorbent paper, is positioned over the reagent layer and acts to rapidly distribute the blood over the reagent layer. In some applications this dispersing layer could incorporate additional reagents. [0069]
  • For glucose determination, cells utilizing the coplanar design were constructed having the reagent layer containing the following formulations: I [0070]
    Glucose oxidase 600 units/ml
    Potassium Ferricyanide 0.4 M
    Phosphate Buffer 0.1 M
    Potassium Chloride 05 M
    Gelatin 2.0 g/dl
  • This was produced by coating a membrane filter with a solution of the above composition and air drying. The reagent layer was then cut into strips that just fit the window opening of the cells and these strips were placed over the electrodes exposed within the windows. A wicking layer of a non-woven rayon fabric was then placed over this reagent layer and held in place with an overlay tape. [0071]
  • As will now be readily appreciated by those of ordinary skill in the art, the enzyme (i.e., glucose oxidase) is sufficient in type and amount to catalyze the reaction (i.e., receive at least one electron from the reaction) involving the enzyme, the analyte (i.e., glucose) and the oxidized form of the redox mediator (i.e., ferricyanide). Optionally, surfactant can also be used in the reagent layer to promote wetting of the reagent by the sample containing the analyte. [0072]
  • In order to prove the application of the technology according to the present invention, a large number of examples were run in aqueous solution at 25° C. The electrolyte consisted of a phosphate buffer of pH 6.8 which was about 0.1 molar total phosphate and 0.5M potassium chloride reagent. The potentials are referenced to a normal hydrogen electrode (NHE). In these tests it was found that any potential between approximately +0.8 and 1.2 volt (vs NHE) is suitable for the quantification of hydroquinone when benzoquinone is used as the oxidant. The limiting currents are proportional to hydroquinone concentrations in the range between 0.0001M and 0.050M. [0073]
  • Detennination of glucose by Cottrell current (i[0074] t) microchronoamperometry with the present method is created in the reaction of hydroquinone to benzoquinone. Cottrell currents decay with time in accordance with the equation:
  • i rt1/2=const
  • where t denotes time. [0075]
  • The main difference between these two techniques consists of applying the appropriate controlled potential after the glucose-benzoquinone reaction is complete and correlating glucose concentrations with Cottrell currents measured at a fixed time thereafter. The current-time readout is shown in FIG. 7. Proportionality between glucose concentrations and Cottrell currents (recorded at t=30 seconds after the application of potential) is shown in FIG. 6. [0076]
  • It should be noted that Cottrell chronoamperometry of metabolites needs the dual safeguards of enzymatic catalysis and controlled potential electrolysis. Gluconic acid yields of 99.9+ percent were attained in the presence of glucose oxidase. Concomitantly, equivalent amounts of benzoquinone were reduced to hydroquinone, which was conveniently quantitated in quiescent solutions, at stationary palladium thin film anodes or sample cells. [0077]
  • The results of these many tests demonstrates the microchronoamperometric methodology of the present invention and its practicality for glucose self-monitoring by diabetics. [0078]
  • In a presently preferred embodiment of the invention utilizing ferricyanide, a number of tests were run showing certain improved operating capabilities. [0079]
  • Referring to FIG. 8, a schematic diagram of a [0080] preferred circuit 15 for use in the apparatus 10 is shown. Circuit 15 includes a microprocessor and LCD panel 16. The working and reference electrodes on the sample cell 20 make contact at contacts W (working electrode) and R (reference electrode), respectively. Voltage reference 41 is connected to battery 42 through analogue power switchb 43. Current from electrodes W and R is converted to a voltage by op amp 45. That voltage is converted into a digital signal (frequency) by a voltage to frequency converter 46 electrically connected to the microprocessor 48. The microprocessor 48 controls the timing of the signals. Measurement of current flow is converted by microprocessor 48 to equivalent glucose, cholesterol or other substance concentrations. Other circuits within the skills of a practiced engineer can now be utilized to obtain the advantages of the present invention.
  • With regard to FIG. 9, [0081] cell 400 consists of coplanar first (i.e., working) 426 and second (i.e., reference) 424 electrodes laminated between an upper 422 and lower 423 nonconducting (i.e., electrically insulating) material. Lamination is on an adhesive layer 425. The upper material 422 includes a die cut opening 428 which, along with the width of the working electrode material defines the working electrode area and provides (with an overlapping reagent layer not depicted) the sampling port of the cell. As illustrated, this die-cut opening is rectangular or square, which has proven advantageous from the standpoint of reproduceability, as such openings are more readily centered over the co-planar electrodes than circular openings. At one end of cell 400 is an open area 427 similar to end position 27 of FIG. 2. In the case of same size (i.e., same surface area first and second electrodes 426, 424 as illustrated in FIG. 10), the opening 428 insures that equal surface areas of the first and second electrodes are exposed.
  • The efficiency of using the apparatus according to the present invention to provide a means for in-home self testing by patients such as diabetics (in the preferred embodiment) can be seen in the following table in which the technology according to the present invention is compared to four commercially available units. As will be seen, the present invention is simpler, and in this instance simplicity breeds consistency in results. [0082]
    GLUCOSE SYSTEM COMPARISONS
    Present
    Steps
    1 2 3 4 Invention
    Turn Instrument On X X X X X
    Calibrate Instrument X X
    Finger Puncture X X X X X
    Apply Blood X X X X X
    Initiate Timing X X X
    Sequence Blot X X X
    Insert Strip to Read X X X X
    Read Results X X X X X
    Total Steps Per 8 8 7 5 4
    Testing
    Detection System RS′ RS RS RS Polaro-
    graphic
    Range (mg/dl) CV″ 10-400 40-400 25-450 40-400 0-1000
    Hypoglycemic 15% 15% 5%
    Euglycemic
    10% 10% 3%
    Hyperglycermic
    5% 5% 2%
    Correlation 0.921 0.862 0.95
  • Thus, while we have illustrated and described the preferred embodiment of our invention, it is to be understood that this invention is capable of variation and modification, and we therefore do not wish or intend to be limited to the precise terms set forth, but desire and intend to avail ourselves of such changes and alterations which may be made for adapting the present invention to various usages and conditions. Accordingly, such changes and alterations are properly intended to be within the full range of equivalents, and therefore within the purview, of the following claims. The terms and expressions which have been employed in the foregoing specifications are used therein as terms of description and not of limitation, and thus there is no intention, in the use of such terms and expressions, of excluding equivalents of the features shown and described or portions thereof, it being recognized that the scope of the invention is defmed and limited only by the claims which follow. [0083]
  • Having thus described our invention and the manner and process of making and using it in such full, clear, concise, and exact terms so as to enable any person skilled in the art to which it pertains, or to with which it is most nearly connected, to make and use the same. [0084]

Claims (66)

We claim:
1. A sample cell for determining the concentration of a selected compound in a sample aqueous fluid, comprising
a first electrode which acts as a working electrode.
a second electrode of substantially the same size as said first electrode and being made of the same electrically conducting material as said first electrode, said second electrode being operatively associated with said first electrode, and
at least one non-conducting layer member having an opening therethrough, said layer member being disposed in contact with at least one of said electrodes and said layer member being sealed against at least one of said first and second electrodes to form a known electrode area within said opening such that said opening forms a well to receive said sample aqueous fluid and to place said fluid in said known electrode area in contact with said first electrode and second electrode, whereby substantially the entire contents of said well is capable of being substantially simultaneously subjected to a predetermined reaction.
2. The sample cell of claim 1 wherein said first and second electrodes comprise palladium.
3. The sample cell of claim 1 wherein said second electrode is a reference electrode.
4. An apparatus for measuring compounds in a sample fluid, comprising
a) a housing having an access opening therethrough.
b) a sample cell receivable into said access opening of said housing, said sample cell being composed of
a first electrode which acts as a working electrode,
a second electrode which acts to fix the system potential and provide opposing current flow with respect to said first electrode, said second electrode being of substantially the same size as said first electrode and being made of the same electrically conducting material as said first electrode, said second electrode being operatively associated with said first electrode,
at lease one non-conducting layer member having an opening therethrough, said layer member being and said layer member being sealed against at least one of said first and second electrode to form a known electrode area within said opening such that said opening forms a well to receive said sample fluid and to place said fluid in said known electrode area in contact with said first electrode and said second electrode,
(c) means for applying an electrical potential to said first electrode and said second electrode,
(d) means for creating an electrical circuit between said first electrode and said second electrode through said sample,
(e) means for measuring Cottrell current through said sample and
(f) means for visually displaying results of said measurement.
5. The apparatus of claim 4 further including means for obtaining a plurality of readings of current in said sample over a plurality of measurement times, after said sample fluid has ben placed in said well.
6. The cell of claim 1, said cell also including a reagent layer positioned within said well created by said opening.
7. The cell of claim 6 wherein said reagent layer contains an oxidant, a buffer and a binding agent.
8. The cell of claim 7 wherein said reagent layer is a layer of said oxidant, buffer and binding agent coated onto a porous matrix and said matrix is positioned within said cell.
9. The cell of claim 8 wherein said reagent layer is a mixture of said oxidant, buffer and binding agent deposited directly into said cell.
10. The cell of claim 7 wherein said oxidant is selected from the group consisting of benzoquinone, ferricyanide, ferricinium, Cobalt (III) orthophenanthroline, and Cobalt (III) dipyridyl.
11. The cell of claim 7 wherein said reagent layer also includes an enzyme and said enzyme is an oxidoreductase.
12. The cell of claim 1 wherein said first electrode and said second electrode comprises a nonconducting substrate to which said electrically conducting material has been applied, wherein said electrically conducting material is the same for each electrode and selected from the group consisting of platinum, gold, palladium, silver and carbon.
13. The cell of claim 1 wherein a first non-conducting layer member has an opening therethrough and is positioned on said first electrode, and said first electrode is positioned on said second electrode, and said second electrode being positioned on a second non-conducting layer member.
14. The cell of claim 1 wherein said first layer member includes a plurality of notches therein exposing and defining an electrical contact area on said first electrode, and said first electrode has a notch therein to expose and define an electrical contact area on said second electrode.
15. The cell of claim 1 wherein said first and second electrodes are co-planarly positioned on a single substrate.
16. The cell of claim 1 wherein said second electrode has circular opening therein and said opening of said layer member is concentric with said opening of said layer member is concentric with said openings of said second electrode, and said opening in said second electrode is of smaller diameter than said opening of said layer member whereby a circular functional electrode area is defined on said second electrode, and said first electrode is positioned beneath said second electrode such that said opening in said second electrode exposes and defines a functional electrode area on said first electrode.
17. The apparatus of claim 13 also comprising means for initiating an electrical potential upon insertion of said sample aqueous fluid to detect the presence of said sample aqueous fluid, and said initiating means also having means for signaling microprocessor means to commence a reaction timing sequence when the presence of said sample aqueous fluid is detected, and means for removing said potential during said reaction timing sequence.
18. A method of measuring the amount of a selected compound in body fluids comprising:
a) providing a measuring cell having at least a first and second electrode of substantially the same size and made of the same electrically conductive material, said cell further containing an oxidant and a buffer,
b) placing a sample of fluid to be tested in said cell,
c) reconstituting said oxidant and buffer with said sample fluid to generate a predetermined reaction,
d) allowing said reaction to proceed substantially to completion,
e) applying a potential across said electrodes and sample, and
f) measuring the resulting Cottrell current to determine the concentration of said selected compound present in said sample.
19. The method as set forth in claim 18 including providing as said first electrode a working electrode and as said second electrode a reference electrode.
20. The method of claim 18 including also providing in said cell and enzyme as a catalyst and said enzyme is an oxidoreductase.
21. A method for measuring the amount of glucose in blood, comprising
a) providing a measuring cell having at least a f irst and second electrode of substantially the same size and made of the same electrically conductive material, said cell further containing an oxidant, a buffer and an enzyme,
b) placing a blood sample to be tested in said cell,
c) reconstituting said oxidant, buffer and enzyme with said blood sample to generate a predetermined reaction,
d) essentially immediately applying a potential across said electrodes and blood sample, and
e) measuring the resultant Cottrell current when the reaction has proceeded to completion to determine the concentration of said glucose present in said blood sample.
22. The method of claim 21 including selecting said oxidant from the group consisting of benzoquinone, ferricyanide, ferricinium, Cobalt (III) orthophenanthroline, and Cobalt (III) dipyridyl.
23. The method of claim 21 including selecting said oxidant from the group consisting of benzoquinone, ferricyanide, ferricinium, Cobalt (III) orthophenanthroline, and Cobalt (III) dipyridyl.
24. The method of claim 21 including providing as said first electrode a working electrode and said second electrode a reference electrode.
25. The method of claim 21 including adding as said enzyme, glucose oxydase.
26. The method of claim 1 wherein in step b) said placing of the blood sample to be tested in the cell generates a current and initiates a timing sequence, and wherein the reaction of step d) is allowed to proceed with an open circuit between said first and second electrode.
27. The method of claim 18 wherein the measuring of said Cottrell current includes obtaining a plurality of readings of current in said cell over a plurality of measurement times after said potential has been applied across said electrodes.
28. A method of measuring the amount of an analyte in a fluid sample, comprising:
a. adding the fluid sample to an electrochemical cell having at least a first and second electrode of substantially the same size and comprising the same electrically conductive material, said electrochemical cell including an electron transfer agent that will react in a reaction involving the analyte, thereby forming a detectable species;
b. incubating the reaction involving analyte and electron transfer agent in an open circuit for a specified period of time;
c. applying a sufficient potential difference between the electrodes of the electrochemical cell, after the incubation step, to readily transfer at least one electron between the detectable species and one of the electrodes, thereby resulting in a Cottrell current;
d. measuring the Cottrell current; and
e. correlating the measured Cottrell current to the amount of analyte in the fluid sample.
29. The method of claim 28, wherein adding the fluid sample to the electrochemical cell causes a sudden charging current, which automatically initiates incubation step b) performed under open circuit.
30. The method of claim 29, wherein the Cottrell current is measured at a preset time following the incubation step.
31. The method of claim 28, wherein the electrochemical cell further includes a catalyst in sufficient amount to catalyze the reaction involving the analyte and the electron transfer agent.
32. The method of claim 31, wherein the catalyst is an enzyme.
33. The method of claim 32, wherein the analyte is glucose and the enzyme is glucose oxidase.
34. The method of claim 28, wherein the electron transfer agent is included in a reagent layer that is coated directly onto the electrochemical cell or is incorporated into a supporting matrix that is placed into the electrochemical cell.
35. The method of claim 34, wherein the supporting matrix is filter paper, membrane, filter, woven fabric, or nonwoven fabric.
36. The method of claim 34, wherein the reagent layer further includes a binder.
37. The method of claim 36, wherein the binder is gelatin, carrageenan, methylcellulose, polyvinyl alcohol, or polyvinylpyrrolidone.
38. The method of claim 37, wherein a dispersing, spreading, or wicking layer overlays the reagent layer.
39. The method of claim 34, wherein adding the fluid sample to the electrochemical cell causes a sudden charging current, which automatically initiates incubation step b) performed under open circuit.
40. The method of claim 39, wherein the Cottrell current is measured at a preset time following the incubation step.
41. The method of claim 40, wherein the reagent layer further includes an enzyme catalyst in sufficient amount to catalyze the reaction involving the analyte and the electron transfer agent.
42. The method of claim 41, wherein the analyte is glucose in a concentration from about 1 milligram glucose per deciliter of fluid sample to about 1000 milligrams glucose per deciliter of fluid sample, and the fluid sample is blood.
43. The method of claim 42, wherein the electron transfer agent is ferricyanide, ferricinium, cobalt (III) orthophenanthroline, cobalt (III) dipyridyl, or benzoquinone.
44. The method of claim 28, wherein the analyte is glucose, TSH, T4, a hormone, a cardiac glycoside, an antiarrhythmic, an antiepileptic, an antibiotic, cholesterol, or a non-therapeutic drug.
45. The method of claim 28, wherein the measuring of said Cottrell current includes obtaining a plurality of readings of current in said cell over a plurality of measurement times after said potential has been applied between said electrodes.
46. A method of measuring the amount of an analyte in a fluid sample, comprising:
a. adding the fluid sample to an electrochemical cell that includes
at least a first and second electrode of substantially the same size and comprising the same electrically conductive material, wherein the conductive material is selected from the group consisting of palladium, platinum, gold, silver, and carbon,
an electron transfer agent,
a first catalyst in sufficient amount to catalyze a first reaction involving the analyte, and
a second catalyst in sufficient amount to catalyze a second reaction involving a product of the first reaction and the electron transfer agent, thereby forming a detectable species;
b. incubating the first and second reactions in an open circuit for a specified period of time;
c. applying a sufficient potential difference between electrodes of the electrochemical cell, after the incubation step, to readily transfer at least one electron between the detectable species and one of the electrodes, thereby resulting in a Cottrell current;
d. measuring the Cottrell current; and
e. correlating the measured Cottrell current to the amount of analyte in the fluid sample.
47. The method of claim 46, wherein adding the fluid sample to the electrochemical cell causes a sudden charging current, which automatically initiates incubation step b) performed under open circuit.
48. The method of claim 47, wherein the Cottrell current is measured at a preset time following the incubation step.
49. A method of measuring the amount of an analyte in a fluid sample, comprising:
a. adding the fluid sample to an electrochemical cell that includes
first and second electron transfer agents,
a first catalyst in sufficient amount to catalyze a first reaction involving the analyte,
a second catalyst in sufficient amount to catalyze a second reaction involving a product of the first reaction and the first electron transfer agent, thereby forming an intermediate species that reacts with the second electron transfer agent, thereby forming a detectable species;
b. incubating the reactions of step a) in an open circuit for a specified period of time;
c. applying a sufficient potential difference between electrodes of the electrochemical cell having substantially the same surface area and comprising the same material, after the incubation step, to readily transfer at least one electron between the detectable species and one of the electrodes, thereby resulting in a Cottrell current;
d. measuring the Cottrell current; and
e. correlating the measured Cottrell current to the amount of analyte in the fluid sample.
50. The method of claim 49, wherein the measuring of said Cottrell current includes obtaining a plurality of readings of current in said cell over a plurality of measurement times after said potential has been applied between said electrodes.
51. A method for measuring the amount of a selected compound in a fluid sample, comprising:
providing a measuring cell having at least first and second electrodes of substantially the same size and comprising the same electrically conductive material, for contact with the fluid sample introduced into the cell,
applying a potential to the electrodes to detect the presence of the fluid sample in the cell,
placing the fluid sample into the cell,
removing the potential to the electrode after the fluid sample is detected in the cell,
selectively oxidizing the compound in the fluid sample with an oxidized electron acceptor to produce an oxidized form of the selected compound and a reduced electron acceptor, and
re-applying a potential across the cell electrodes and measuring the resulting Cottrell current, said current being proportional to the concentration of the reduced electron acceptor and the selected compound in the fluid sample.
52. A method for measuring the amount of glucose in blood, comprising:
providing a measuring cell consisting of first and second electrodes for contact with blood introduced into the cell, said electrodes being of substantially the same size and comprising the same electrically conductive material,
applying a potential across the electrodes,
placing a volume of blood into the cell,
removing the potential across the electrodes after the volume of blood is placed into the measuring cell,
oxidizing the glucose in the blood with an oxidized electron acceptor in the presence of glucose oxidase to produce gluconic acid and a reduced electron acceptor,
re-applying a potential across the measuring cell electrodes, and
measuring the Cottrell current through the cell, the Cottrell current being proportional to the glucose concentration in the blood.
53. The method of claim 52, wherein placing the fluid sample into the measuring cell causes a sudden charging current, which automatically initiates removal of the potential from the electrodes and performance of the selective oxidation of the selected compound under open circuit.
54. The method of claim 53, wherein the Cottrell current is measured at the preset time after re-application of a potential across the measuring cell electrodes.
55. The method of claim 52, wherein placing the volume of blood into the measuring cell causes a sudden charging current, which automatically initiates removal of the potential across the electrodes and performance of the oxidation of glucose in the blood under open circuit.
56. The method of claim 55, wherein the Cottrell current is measured at a preset time after re-application of a potential across the measuring cell electrodes.
57. The method of claim 56, wherein the measuring of Cottrell current includes obtaining a plurality of readings of current in said cell after a plurality of pre-set measurement times after said potential has been applied across said measuring cell electrodes.
58. A device for analyzing an analyte, comprising:
a. a first electrical insulator;
b. a pair of electrodes consisting of working and second electrodes of substantially the same size, the electrodes being made of the same electrically conducting materials and being supported on the first electrical insulator;
c. a second electrical insulator, overlaying the first electrical insulator and the electrodes and including a cutout portion that exposes substantially equal surface areas of the working and second electrodes; and
d. a reagent substantially covering the exposed electrode surfaces in the cutout portion and comprising the oxidized form of a redox mediator, an enzyme, and a buffer,
the oxidized form of the redox mediator being of sufficient type to receive at least one electron from a reaction involving enzyme, analyte, and oxidized form of the redox mediator and being in sufficient excess to insure that the diffusion limited electrooxidation of the redox mediator at the working electrode surface is the principle limiter of current flow through the device and to resist a shift in potential between the electrodes,
the enzyme being of sufficient type and in sufficient amount to catalyze the reaction involving enzyme, analyte, and oxidized form of the redox mediator, and
the buffer being unreactive with respect to the reduced and oxidized form of the redox mediator and being of sufficient type and in sufficient amount to provide and maintain a pH at which the enzyme catalyzes the reaction involving enzyme, analyte, and oxidized form of the redox mediator.
59. A reagent incorporated into a sample receiving portion of an electrochemical device that measures an analyte and that has a pair of electrodes consisting of working and second electrodes of substantially the same size, the electrodes being made of the same electrically conducting materials and having substantially equal surface areas in the sample receiving portion, comprising:
the oxidized form of a redox mediator, an enzyme, and a buffer,
the oxidized form of the redox mediator being of sufficient type to receive at least one electron from a reaction involving enzyme, analyte, and oxidized form of the redox mediator and being in sufficient amount to insure that current produced by diffusion limited electrooxidation is limited by the oxidation of the reduced form of the redox mediator at the working electrode surface,
the enzyme being of sufficient type and in sufficient amount to catalyze the reaction involving enzyme, analyte, and oxidized form of the redox mediator, and
the buffer having a higher oxidation potential than the reduced form of the redox mediator and being of sufficient type and in sufficient amount to provide and maintain a pH at which the enzyme, analyte, and oxidized form of the redox mediator.
60. A reagent incorporated into a sample receiving portion of an electrochemical device that measures an analyte and that has a pair of electrodes consisting of working and second electrodes of substantially the same size, the electrodes being made of the same electrically conducting materials and having substantially equal surface areas in the sample receiving portion, comprising:
the reduced form of a redox mediator, an enzyme, and buffer,
the reduced form of a redox mediator being of sufficient type to donate at least one electron from a reaction involving enzyme, analyte, and reduced form of the redox mediator and being in sufficient amount to insure that current produced by diffusion limited electroreduction is limited by the reduction of the oxidized form of the redox mediator at the working electrode surface,
the enzyme being of sufficient type and in sufficient amount to catalyze the reaction involving enzyme, analyte, and the reduced form of the redox mediator, and
the buffer having a lower reduction potential than the oxidized form of the redox mediator and being of sufficient type and in sufficient amount to provide and maintain a pH at which the enzyme catalyzes the reaction involving enzyme, analyte, and the reduced form of the redox mediator.
61. A method of determining the concentration of an analyte in a fluid, comprising the steps of:
a. contacting the fluid with a reagent that covers substantially equal surface areas of first and second electrodes and includes the oxidized form of a redox mediator, an enzyme, and a buffer,
the oxidized form of the redox mediator being of sufficient type to receive at least one electron from a reaction involving enzyme, analyte, and oxidized form of the redox mediator and being in sufficient amount to insure that current produced by diffusion limited electrooxidation is limited by the oxidation of the reduced form of the redox mediator at the working electrode surface,
the enzyme being of sufficient type and in sufficient amount to catalyze the reaction involving enzyme, analyte, and the oxidized form of the redox mediator, and
the buffer having a higher oxidation potential than the reduced form of the redox mediator and being of sufficient type and in sufficient amount to provide and maintain a pH at which the enzyme catalyzes the reaction involving enzyme, analyte, and the oxidized form of the redox mediator;
b. allowing the reaction involving the enzyme, analyte, and the oxidized form of the redox mediator to go to completion;
c. subsequently applying a potential difference between the electrodes sufficient to cause diffusion limited electrooxidation of the reduced form of the redox mediator at the surface of the first electrode;
d. thereafter measuring the resulting diffusion limited current; and
e. correlating the current measurement to the concentration of the analyte in the fluid.
62. The method of claim 61, wherein the reagent further includes a supporting matrix material of sufficient type and in sufficient amount to disperse the redox mediator in the reagent.
63. The method of claim 62, wherein the reagent further includes a surfactant of sufficient type and in sufficient amount to wet the fluid upon contact with the reagent.
64. The method of claim 63, wherein the analyte is glucose, the oxidized form of the redox mediator is ferricyanide, the buffer is phosphate, and the supporting matrix delays dissolution of the reagent until said reagent has adsorbed said fluid.
65. The apparatus of claim 8, further including a wicking layer positioned over said reagent layer and held in place with an overlay tape.
66. The apparatus of claim 1, wherein the first and second electrodes are spaced apart by a distance of at least about O.lmm and at most about lcm.
US10/123,414 1995-02-09 2002-04-17 Apparatus for amperometric diagnostic anagnostic analysis Abandoned US20030159944A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/123,414 US20030159944A1 (en) 1995-02-09 2002-04-17 Apparatus for amperometric diagnostic anagnostic analysis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/386,919 US6153069A (en) 1995-02-09 1995-02-09 Apparatus for amperometric Diagnostic analysis
US09/696,253 US6413411B1 (en) 1995-02-09 2000-10-26 Method and apparatus for amperometric diagnostic analysis
US10/123,414 US20030159944A1 (en) 1995-02-09 2002-04-17 Apparatus for amperometric diagnostic anagnostic analysis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/696,253 Continuation US6413411B1 (en) 1995-02-09 2000-10-26 Method and apparatus for amperometric diagnostic analysis

Publications (1)

Publication Number Publication Date
US20030159944A1 true US20030159944A1 (en) 2003-08-28

Family

ID=23527629

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/386,919 Expired - Lifetime US6153069A (en) 1995-02-09 1995-02-09 Apparatus for amperometric Diagnostic analysis
US09/696,253 Expired - Lifetime US6413411B1 (en) 1995-02-09 2000-10-26 Method and apparatus for amperometric diagnostic analysis
US10/123,414 Abandoned US20030159944A1 (en) 1995-02-09 2002-04-17 Apparatus for amperometric diagnostic anagnostic analysis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/386,919 Expired - Lifetime US6153069A (en) 1995-02-09 1995-02-09 Apparatus for amperometric Diagnostic analysis
US09/696,253 Expired - Lifetime US6413411B1 (en) 1995-02-09 2000-10-26 Method and apparatus for amperometric diagnostic analysis

Country Status (1)

Country Link
US (3) US6153069A (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080073225A1 (en) * 2004-06-29 2008-03-27 Christian Paulus Process and Device for Emulating a Counter-Electrode in a Monolithically Integrated Electrochemical Analysis System
WO2008051742A2 (en) * 2006-10-24 2008-05-02 Bayer Healthcare Llc Transient decay amperometry
US20080182338A1 (en) * 2005-11-17 2008-07-31 Klaus Abraham-Fuchs Apparatus and process for processing a sample
WO2009021908A2 (en) * 2007-08-10 2009-02-19 Unilever Plc Disposable enzymatic sensor for liquid samples
US20090145775A1 (en) * 2007-12-10 2009-06-11 Bayer Healthcare Llc Reagents and methods for detecting analytes
US20090151864A1 (en) * 2003-06-20 2009-06-18 Burke David W Reagent stripe for test strip
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7666149B2 (en) 1997-12-04 2010-02-23 Peliken Technologies, Inc. Cassette of lancet cartridges for sampling blood
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7731729B2 (en) 2002-04-19 2010-06-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US7833171B2 (en) 2002-04-19 2010-11-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7841992B2 (en) 2001-06-12 2010-11-30 Pelikan Technologies, Inc. Tissue penetration device
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7862520B2 (en) 2002-04-19 2011-01-04 Pelikan Technologies, Inc. Body fluid sampling module with a continuous compression tissue interface surface
US7874994B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909775B2 (en) 2001-06-12 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7959582B2 (en) 2002-04-19 2011-06-14 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8092668B2 (en) 2004-06-18 2012-01-10 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8287703B2 (en) 1999-10-04 2012-10-16 Roche Diagnostics Operations, Inc. Biosensor and method of making
US8333710B2 (en) 2002-04-19 2012-12-18 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102854230A (en) * 2012-09-04 2013-01-02 南京工业大学 Biological detector
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8439872B2 (en) 1998-03-30 2013-05-14 Sanofi-Aventis Deutschland Gmbh Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US8663442B2 (en) 2003-06-20 2014-03-04 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8679853B2 (en) 2003-06-20 2014-03-25 Roche Diagnostics Operations, Inc. Biosensor with laser-sealed capillary space and method of making
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
EP2704633B1 (en) * 2011-05-06 2020-12-02 Medtronic MiniMed, Inc. Method and apparatus for continuous analyte monitoring

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153069A (en) 1995-02-09 2000-11-28 Tall Oak Ventures Apparatus for amperometric Diagnostic analysis
US6413410B1 (en) 1996-06-19 2002-07-02 Lifescan, Inc. Electrochemical cell
AUPN661995A0 (en) 1995-11-16 1995-12-07 Memtec America Corporation Electrochemical cell 2
US6071391A (en) * 1997-09-12 2000-06-06 Nok Corporation Enzyme electrode structure
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6841052B2 (en) 1999-08-02 2005-01-11 Bayer Corporation Electrochemical-sensor design
US7276146B2 (en) 2001-11-16 2007-10-02 Roche Diagnostics Operations, Inc. Electrodes, methods, apparatuses comprising micro-electrode arrays
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
JP2001167908A (en) * 1999-12-03 2001-06-22 Tdk Corp Semiconductor electronic component
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor
AU2006209265B2 (en) * 2000-03-28 2010-05-13 Diabetes Diagnostics, Inc. Rapid response glucose sensor
DE10028692C2 (en) * 2000-06-09 2002-06-06 Micronas Gmbh Procedure for the investigation of membrane-enclosed biocompartments
US20020019880A1 (en) * 2000-07-03 2002-02-14 Takashi Sakakura IP communication system for wireless terminal and communication method for wireless terminal
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
DE60236429D1 (en) * 2001-05-30 2010-07-01 I Sens Inc Biosensor
US6767441B1 (en) * 2001-07-31 2004-07-27 Nova Biomedical Corporation Biosensor with peroxidase enzyme
IL156007A0 (en) 2001-10-10 2003-12-23 Lifescan Inc Electrochemical cell
US7018843B2 (en) * 2001-11-07 2006-03-28 Roche Diagnostics Operations, Inc. Instrument
US20030116447A1 (en) 2001-11-16 2003-06-26 Surridge Nigel A. Electrodes, methods, apparatuses comprising micro-electrode arrays
US6863800B2 (en) * 2002-02-01 2005-03-08 Abbott Laboratories Electrochemical biosensor strip for analysis of liquid samples
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
CA2419213C (en) * 2002-03-07 2011-06-21 Bayer Healthcare Llc Improved electrical sensor
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US6743635B2 (en) * 2002-04-25 2004-06-01 Home Diagnostics, Inc. System and methods for blood glucose sensing
US6964871B2 (en) * 2002-04-25 2005-11-15 Home Diagnostics, Inc. Systems and methods for blood glucose sensing
US6946299B2 (en) * 2002-04-25 2005-09-20 Home Diagnostics, Inc. Systems and methods for blood glucose sensing
US20080112852A1 (en) * 2002-04-25 2008-05-15 Neel Gary T Test Strips and System for Measuring Analyte Levels in a Fluid Sample
US9017544B2 (en) 2002-10-04 2015-04-28 Roche Diagnostics Operations, Inc. Determining blood glucose in a small volume sample receiving cavity and in a short time period
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US7587287B2 (en) 2003-04-04 2009-09-08 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
EP1467206A1 (en) * 2003-04-08 2004-10-13 Roche Diagnostics GmbH Biosensor system
EP1628567B1 (en) 2003-05-30 2010-08-04 Pelikan Technologies Inc. Method and apparatus for fluid injection
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US8007656B2 (en) 2003-10-24 2011-08-30 Bayer Healthcare Llc Enzymatic electrochemical biosensor
WO2005078118A1 (en) 2004-02-06 2005-08-25 Bayer Healthcare Llc Oxidizable species as an internal reference for biosensors and method of use
EP1751533A2 (en) 2004-05-14 2007-02-14 Bayer Healthcare, LLC Voltammetric systems for assaying biological analytes
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US7344626B2 (en) * 2005-04-15 2008-03-18 Agamatrix, Inc. Method and apparatus for detection of abnormal traces during electrochemical analyte detection
US7645374B2 (en) * 2005-04-15 2010-01-12 Agamatrix, Inc. Method for determination of analyte concentrations and related apparatus
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
GB0509919D0 (en) * 2005-05-16 2005-06-22 Ralph Ellerker 1795 Ltd Improvements to door closure system
MX2008000836A (en) 2005-07-20 2008-03-26 Bayer Healthcare Llc Gated amperometry.
EP1934591B1 (en) 2005-09-30 2019-01-02 Ascensia Diabetes Care Holdings AG Gated voltammetry
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
EP1991112A1 (en) * 2006-02-27 2008-11-19 Bayer Healthcare, LLC Temperature-adjusted analyte determination for biosensor systems
US8529751B2 (en) 2006-03-31 2013-09-10 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7966859B2 (en) 2006-05-03 2011-06-28 Bayer Healthcare Llc Underfill detection system for a biosensor
CN101432620B (en) 2006-05-03 2013-08-14 拜尔健康护理有限责任公司 Underfill detection system for electrochemical biosensor
JP5121822B2 (en) * 2006-05-08 2013-01-16 バイエル・ヘルスケア・エルエルシー Abnormal output detection system for biosensor
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
CA2664186C (en) 2006-09-22 2021-02-23 Bayer Healthcare Llc Biosensor system having enhanced stability and hematocrit performance
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8101062B2 (en) * 2007-07-26 2012-01-24 Nipro Diagnostics, Inc. System and methods for determination of analyte concentration using time resolved amperometry
BRPI0814202B1 (en) * 2007-07-26 2019-10-29 Home Diagnostics Inc methods and systems for determining the concentration of analytical fluid sample
WO2009042631A2 (en) 2007-09-24 2009-04-02 Bayer Healthcare Llc Multi-electrode test sensors
US8778168B2 (en) 2007-09-28 2014-07-15 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
CN101896619B (en) 2007-12-10 2017-04-05 安晟信医疗科技控股公司 Rapid-read gated amperometry
CN103760356B (en) 2007-12-10 2019-06-28 安晟信医疗科技控股公司 Slope-based compensation
US8603768B2 (en) 2008-01-17 2013-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
WO2009119117A1 (en) * 2008-03-27 2009-10-01 パナソニック株式会社 Measurement device, measurement system, and concentration measurement method
US8551320B2 (en) 2008-06-09 2013-10-08 Lifescan, Inc. System and method for measuring an analyte in a sample
CN102089650B (en) * 2008-07-10 2014-01-29 拜尔健康护理有限责任公司 Systems and methods including amperometric and voltammetric duty cycles
CN101470094B (en) * 2008-09-09 2012-12-05 中国科学院金属研究所 Method for measuring pH value of high-temperature high-pressure water solution
JP5738770B2 (en) 2008-12-08 2015-06-24 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC Biosensor system with signal conditioning
EP2373805B1 (en) 2008-12-08 2015-11-04 Bayer HealthCare LLC Low total salt reagent compositions and systems for biosensors
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
MX2012005412A (en) * 2009-11-10 2012-08-15 Bayer Healthcare Llc Underfill recognition system for a biosensor.
MX2012010860A (en) * 2010-03-22 2013-03-05 Bayer Healthcare Llc Residual compensation for a biosensor.
MX339815B (en) 2010-06-07 2016-06-13 Ascensia Diabetes Care Holdings Ag Underfill management system for a biosensor.
BR112012031166A2 (en) 2010-06-07 2018-02-27 Bayer Healthcare Llc slope-based compensation including secondary output signals
WO2012164271A1 (en) * 2011-05-27 2012-12-06 Lifescan Scotland Limited Peak offset correction for analyte test strip
WO2013043839A1 (en) 2011-09-21 2013-03-28 Bayer Healthcare Llc Biosensor with error compensation
CA2840640C (en) 2011-11-07 2020-03-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods
RU2489710C1 (en) * 2012-02-20 2013-08-10 Владимир Вадимович Мошкин Switching chronoamperometry method
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US9933441B2 (en) 2013-03-14 2018-04-03 Ascensia Diabetes Care Holdings Ag Progressive approximation of sample analyte concentration
ES2812806T3 (en) 2013-03-14 2021-03-18 Ascensia Diabetes Care Holdings Ag Standard calibration of analyte concentration determinations
EP2972397B1 (en) 2013-03-14 2021-10-13 Ascensia Diabetes Care Holdings AG System error compensation of analyte concentration determinations
WO2015121887A1 (en) * 2014-02-14 2015-08-20 Elements S.R.L. High sensitivity multichannel detection device
CN107743584B (en) * 2015-06-15 2021-02-19 豪夫迈·罗氏有限公司 Method and test element for the electrochemical detection of at least one analyte in a body fluid sample
CN110678746A (en) * 2017-05-03 2020-01-10 戴卫凯尔有限公司 Disposable electrochemical sensing strips and related methods
US11099151B2 (en) * 2017-05-05 2021-08-24 neoSense Technologies AB Oxygen sensor
US11448674B2 (en) * 2019-10-04 2022-09-20 Roche Diabetes Care, Inc. System and method for detection of contact with a test strip using capacitive sensing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007632A1 (en) * 1985-06-21 1986-12-31 Matsushita Electric Industrial Co., Ltd. Biosensor and method of manufacturing same
US5128015A (en) * 1988-03-15 1992-07-07 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5108564A (en) * 1988-03-15 1992-04-28 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US4995402A (en) * 1988-10-12 1991-02-26 Thorne, Smith, Astill Technologies, Inc. Medical droplet whole blood and like monitoring
US5508171A (en) * 1989-12-15 1996-04-16 Boehringer Mannheim Corporation Assay method with enzyme electrode system
US5288636A (en) * 1989-12-15 1994-02-22 Boehringer Mannheim Corporation Enzyme electrode system
US5243516A (en) * 1989-12-15 1993-09-07 Boehringer Mannheim Corporation Biosensing instrument and method
US5385846A (en) * 1993-06-03 1995-01-31 Boehringer Mannheim Corporation Biosensor and method for hematocrit determination
US5522977A (en) * 1994-10-07 1996-06-04 Biomedix, Inc. Glucose sensor
US6153069A (en) 1995-02-09 2000-11-28 Tall Oak Ventures Apparatus for amperometric Diagnostic analysis

Cited By (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666149B2 (en) 1997-12-04 2010-02-23 Peliken Technologies, Inc. Cassette of lancet cartridges for sampling blood
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US8439872B2 (en) 1998-03-30 2013-05-14 Sanofi-Aventis Deutschland Gmbh Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8551308B2 (en) 1999-10-04 2013-10-08 Roche Diagnostics Operations, Inc. Biosensor and method of making
US8287703B2 (en) 1999-10-04 2012-10-16 Roche Diagnostics Operations, Inc. Biosensor and method of making
US8360991B2 (en) 2001-06-12 2013-01-29 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7841992B2 (en) 2001-06-12 2010-11-30 Pelikan Technologies, Inc. Tissue penetration device
US8679033B2 (en) 2001-06-12 2014-03-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8641643B2 (en) 2001-06-12 2014-02-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US8622930B2 (en) 2001-06-12 2014-01-07 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8845550B2 (en) 2001-06-12 2014-09-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7981055B2 (en) 2001-06-12 2011-07-19 Pelikan Technologies, Inc. Tissue penetration device
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US8382683B2 (en) 2001-06-12 2013-02-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7909775B2 (en) 2001-06-12 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US8343075B2 (en) 2001-06-12 2013-01-01 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US8282577B2 (en) 2001-06-12 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US8216154B2 (en) 2001-06-12 2012-07-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8211037B2 (en) 2001-06-12 2012-07-03 Pelikan Technologies, Inc. Tissue penetration device
US8206317B2 (en) 2001-06-12 2012-06-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8206319B2 (en) 2001-06-12 2012-06-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8162853B2 (en) 2001-06-12 2012-04-24 Pelikan Technologies, Inc. Tissue penetration device
US7850622B2 (en) 2001-06-12 2010-12-14 Pelikan Technologies, Inc. Tissue penetration device
US8123700B2 (en) 2001-06-12 2012-02-28 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9802007B2 (en) 2001-06-12 2017-10-31 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8016774B2 (en) 2001-06-12 2011-09-13 Pelikan Technologies, Inc. Tissue penetration device
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8430828B2 (en) 2002-04-19 2013-04-30 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909774B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US7938787B2 (en) 2002-04-19 2011-05-10 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7959582B2 (en) 2002-04-19 2011-06-14 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7988644B2 (en) 2002-04-19 2011-08-02 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9498160B2 (en) 2002-04-19 2016-11-22 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8062231B2 (en) 2002-04-19 2011-11-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7874994B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9186468B2 (en) 2002-04-19 2015-11-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7862520B2 (en) 2002-04-19 2011-01-04 Pelikan Technologies, Inc. Body fluid sampling module with a continuous compression tissue interface surface
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8905945B2 (en) 2002-04-19 2014-12-09 Dominique M. Freeman Method and apparatus for penetrating tissue
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8197423B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8202231B2 (en) 2002-04-19 2012-06-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7833171B2 (en) 2002-04-19 2010-11-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8690796B2 (en) 2002-04-19 2014-04-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8414503B2 (en) 2002-04-19 2013-04-09 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8403864B2 (en) 2002-04-19 2013-03-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7731729B2 (en) 2002-04-19 2010-06-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8388551B2 (en) 2002-04-19 2013-03-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus for multi-use body fluid sampling device with sterility barrier release
US8382682B2 (en) 2002-04-19 2013-02-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8333710B2 (en) 2002-04-19 2012-12-18 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8337420B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8251921B2 (en) 2003-06-06 2012-08-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US8083993B2 (en) 2003-06-20 2011-12-27 Riche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8586373B2 (en) 2003-06-20 2013-11-19 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7727467B2 (en) 2003-06-20 2010-06-01 Roche Diagnostics Operations, Inc. Reagent stripe for test strip
US8222044B2 (en) 2003-06-20 2012-07-17 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US7749437B2 (en) 2003-06-20 2010-07-06 Roche Diagnostics Operations, Inc. Method and reagent for producing narrow, homogenous reagent stripes
US8211379B2 (en) 2003-06-20 2012-07-03 Roche Diagnostics Operations, Inc. Test strip with slot vent opening
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8507289B1 (en) 2003-06-20 2013-08-13 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US8293538B2 (en) 2003-06-20 2012-10-23 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7829023B2 (en) 2003-06-20 2010-11-09 Roche Diagnostics Operations, Inc. Test strip with vent opening
US7879618B2 (en) 2003-06-20 2011-02-01 Roche Diagnostics Operations, Inc. Method and reagent for producing narrow, homogenous reagent strips
US8298828B2 (en) 2003-06-20 2012-10-30 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8119414B2 (en) 2003-06-20 2012-02-21 Roche Diagnostics Operations, Inc. Test strip with slot vent opening
US8663442B2 (en) 2003-06-20 2014-03-04 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US8142721B2 (en) 2003-06-20 2012-03-27 Roche Diagnostics Operations, Inc. Test strip with slot vent opening
US8679853B2 (en) 2003-06-20 2014-03-25 Roche Diagnostics Operations, Inc. Biosensor with laser-sealed capillary space and method of making
US20090151864A1 (en) * 2003-06-20 2009-06-18 Burke David W Reagent stripe for test strip
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7892849B2 (en) 2003-06-20 2011-02-22 Roche Diagnostics Operations, Inc. Reagent stripe for test strip
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8945910B2 (en) 2003-09-29 2015-02-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US8296918B2 (en) 2003-12-31 2012-10-30 Sanofi-Aventis Deutschland Gmbh Method of manufacturing a fluid sampling device with improved analyte detecting member configuration
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US8092668B2 (en) 2004-06-18 2012-01-10 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US9410915B2 (en) 2004-06-18 2016-08-09 Roche Operations Ltd. System and method for quality assurance of a biosensor test strip
US8617382B2 (en) * 2004-06-29 2013-12-31 Siemens Aktiengesellschaft Process and device for emulating a counter-electrode in a monolithically integrated electrochemical analysis system
US20080073225A1 (en) * 2004-06-29 2008-03-27 Christian Paulus Process and Device for Emulating a Counter-Electrode in a Monolithically Integrated Electrochemical Analysis System
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US8551424B2 (en) * 2005-11-17 2013-10-08 Siemens Aktiengesellschaft Apparatus for processing a sample comprising a biochip and reagents embedded in a biodegradable material, and processes thereof
US20080182338A1 (en) * 2005-11-17 2008-07-31 Klaus Abraham-Fuchs Apparatus and process for processing a sample
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
WO2008051742A3 (en) * 2006-10-24 2008-06-19 Bayer Healthcare Llc Transient decay amperometry
WO2008051742A2 (en) * 2006-10-24 2008-05-02 Bayer Healthcare Llc Transient decay amperometry
EP2679150A3 (en) * 2006-10-24 2014-11-05 Bayer HealthCare LLC Transient decay amperometry
US8026104B2 (en) 2006-10-24 2011-09-27 Bayer Healthcare Llc Transient decay amperometry
US10190150B2 (en) 2006-10-24 2019-01-29 Ascensia Diabetes Care Holdings Ag Determining analyte concentration from variant concentration distribution in measurable species
US11091790B2 (en) 2006-10-24 2021-08-17 Ascensia Diabetes Care Holdings Ag Determining analyte concentration from variant concentration distribution in measurable species
US8470604B2 (en) 2006-10-24 2013-06-25 Bayer Healthcare Llc Transient decay amperometry
US9005527B2 (en) 2006-10-24 2015-04-14 Bayer Healthcare Llc Transient decay amperometry biosensors
EP3753481A1 (en) * 2006-10-24 2020-12-23 Ascensia Diabetes Care Holdings AG Transient decay amperometry
WO2009021908A3 (en) * 2007-08-10 2009-04-02 Unilever Plc Disposable enzymatic sensor for liquid samples
WO2009021908A2 (en) * 2007-08-10 2009-02-19 Unilever Plc Disposable enzymatic sensor for liquid samples
US10696998B2 (en) 2007-12-10 2020-06-30 Ascensia Diabetes Care Holdings Ag Reagents and methods for detecting analytes
US20090145775A1 (en) * 2007-12-10 2009-06-11 Bayer Healthcare Llc Reagents and methods for detecting analytes
US11180790B2 (en) 2007-12-10 2021-11-23 Ascensia Diabetes Care Holdings Ag Reagents and methods for detecting analytes
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
EP2704633B1 (en) * 2011-05-06 2020-12-02 Medtronic MiniMed, Inc. Method and apparatus for continuous analyte monitoring
CN102854230A (en) * 2012-09-04 2013-01-02 南京工业大学 Biological detector

Also Published As

Publication number Publication date
US6153069A (en) 2000-11-28
US6413411B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
US6413411B1 (en) Method and apparatus for amperometric diagnostic analysis
EP0406304B1 (en) Method and apparatus for amperometric diagnostic analysis
US5108564A (en) Method and apparatus for amperometric diagnostic analysis
USRE36268E (en) Method and apparatus for amperometric diagnostic analysis
US6632349B1 (en) Hemoglobin sensor
JP3819936B2 (en) Electrochemical biosensor test strip
AU2001276888B2 (en) Antioxidant sensor
USRE41264E1 (en) Biosensor with peroxidase enzyme
US6638415B1 (en) Antioxidant sensor
EP1036320B1 (en) Improved electrochemical biosensor test strip
US6258229B1 (en) Disposable sub-microliter volume sensor and method of making
US20040118705A1 (en) Electrochemical test strip having a plurality of reaction chambers and methods for using the same
AU2001276888A1 (en) Antioxidant sensor
EP2770063A1 (en) Glucose electrochemical measurement method with error detection
AU644059B2 (en) Method and apparatus for amperometric diagnostic analysis
JPS6355025B2 (en)
RU2271536C2 (en) Method for measuring hemoglobin quantity
CA1340516C (en) Method and apparatus for amperometric diagnostic analysis
JPH0640087B2 (en) Biosensor
IL153582A (en) Hemoglobin sensor
MXPA97010374A (en) Electroquim biosensor test strip

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION